Cronus Pharma Launches Butorphic® (Butorphanol Tartrate) Sterile Injectable Solution
EAST BRUNSWICK, N.J. — Cronus Pharma LLC, a fully integrated research, development, manufacturing, sales and marketing animal health pharmaceutical company, announces the launch of Butorphic® (Butorphanol Tartrate) Sterile Injectable Solution for immediate availability in the U.S. animal health market through national and regional distributors.
Article content
Article content
'Butorphic is a vital analgesic for managing equine colic pain and we are excited to grow our equine portfolio. Importantly, Butorphic marks our fifth product launch this year, expanding our portfolio to twenty-five products with several more planned for 2025 and beyond,' said Vimal Kavuru, Chairman & CEO.
This launch enhances Cronus Pharma's robust sedative and anesthesia product portfolio which includes AnaSed® Equine (Xylazine) Injection, Cropamezole™ (Atipamezole) Injection, DexmedVet™ (Dexmedetomidine) Injection, DetomiSed™ (Detomidine) Injection, and Ketamine Injection.
Article content
'Butorphic's launch reinforces our position among the animal health leaders in U.S. FDA ANADA approvals over the past several years, which is a testament to our team's dedication to delivering high-quality, cost-effective pharmaceuticals to veterinarians and pet owners,' said Edward Neugeboren, Chief Strategy Officer.
Butorphic is indicated for the relief of pain associated with colic and postpartum pain in adult horses and yearlings. Clinical studies demonstrate that butorphanol tartrate effectively alleviates abdominal pain caused by torsion, impaction, intussusception, spasmodic and tympanic colic, and postpartum pain. Approved by the FDA under ANADA #200-332, Butorphic provides the same efficacy and safety, and is a generic equivalent to the reference product, Torbugesic®. Available in 10 mg/mL concentrations in 20 mL and 50 mL multi-dose vials, our unique 20 mL vial offers veterinarians more flexible dosing options.
Article content
Please refer to the Package Insert for complete prescribing instructions, precautions, and full safety information.
Article content
About Cronus Pharma
Article content
Cronus is a fully integrated research, development, manufacturing, sales and marketing animal health pharmaceutical company
Article content
Article content
headquartered in East Brunswick, New Jersey, dedicated to providing high-quality and cost-effective pharmaceuticals serving the companion, equine and production animal health markets. Through our in-house R&D and acquisitions, Cronus has an extensive product portfolio of seventy-seven US FDA approved products as well as numerous products pending approval and a broad development pipeline. Cronus is proud to be among the leaders in U.S FDA ANADA approvals in the animal health industry over the past several years. Our recently built state of the art manufacturing facility located in Hyderabad, India has broad capabilities including solid oral dose, sterile injectables and cephalosporins. Our products are available to veterinarians and pet owners nationwide through national and regional distributors. Our passionate team is committed to growing our business and being among the leading animal health pharmaceutical companies.
Article content
Article content
Article content
Contacts
Article content
Business Development
Article content
Article content
Mr. Edward Neugeboren
Article content
Article content
Chief Strategy Officer
Article content
Article content
Phone: 732-243-8471
Article content
Article content
Email:
Article content
edwardn@cronuspharmausa.com
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
19 minutes ago
- National Post
Access Advance Announces HEVC Advance and VVC Advance Pricing through 2030
Article content BOSTON — Access Advance LLC ('Advance') today announced the results of several significant decisions by the Licensors in both the HEVC Advance and VVC Advance Patent Pools. Both patent pools opted to maintain their current royalty rates and caps for Licensees who sign before December 31, 2025, and to extend an incentive that aligns the royalty caps for Advance's Multi-Codec Bridging Agreement ('MCBA') and the VVC Advance Patent Pool for Licensees who sign the MCBA during the same period. Article content The result is that Licensees who join the HEVC Advance program, gaining access to more than 27,000 patents, on or before December 31, 2025, can lock in current rates and caps through 2030. This protection applies both to ongoing royalty obligations and calculation of royalties due for past sales. Article content Additionally, both current and new HEVC Advance Licensees who join the VVC Advance Patent Pool and execute the MCBA by December 31, 2025, will enjoy MCBA royalty caps that match the royalty caps for the VVC Advance program. This reflects an extension of an incentive that expired June 30, 2022, and locks in current rates through 2030, effectively reducing the current MCBA royalty caps and reinforcing Access Advance's commitment to rewarding early adopters of its platform licensing approach. Article content Beginning on January 1, 2026, the HEVC royalty rates will be updated to align HEVC Advance pricing with the existing VVC Advance royalty rate structure, which the VVC Advance Licensors voted to maintain at current levels through 2030, making the value proposition of the MCBA even more beneficial for Licensees across Access Advance's video codec platform licensing programs. Article content 'Access Advance is pleased that both groups of Licensors opted for marketplace stability and predictability with their decisions largely to maintain rates and caps at existing levels and providing an additional incentive for Licensees to sign the MCBA. After nearly a decade of stable HEVC rates, the measured adjustment for Licensees joining after 2025 reflects the tremendous growth and value that the HEVC Advance Patent Pool now delivers to the marketplace in light of the increased prevalence of HEVC devices and content,' said Peter Moller, CEO of Access Advance. 'When we launched, we anticipated coverage of approximately 35% of all HEVC standard essential patents. Today, our pool represents an estimated 75-80% of the global HEVC patent landscape – more than doubling our initial projections. The approved rate adjustment of 25%, which will go into effect for new Licensees on January 1, 2026, while less than a full doubling that our coverage would justify, ensures fair compensation for innovators while maintaining our commitment to transparent, FRAND licensing. And, with these changes, there are clear benefits to a company joining our VVC program and securing the MCBA's discounts even if their products do not yet include VVC functionality.' Article content Industry-Leading Patent Coverage Article content The HEVC Advance Patent Pool has evolved from its initial launch with fewer than 500 patents to become the industry's most comprehensive licensing solution, now covering over 27,000 patents essential to H.265/HEVC technology. This dramatic expansion represents the largest consolidation of HEVC standard-essential patents available through any single licensing program globally. Article content The patent pool's success in attracting major patent holders demonstrates the market's confidence in Access Advance's balanced approach to intellectual property licensing. Recent additions include leading technology companies across mobile devices, consumer electronics, automotive, and emerging IOT applications. Article content Opportunity for Flexibility, Savings and Efficiencies Article content Access Advance encourages both current licensees and prospective partners to evaluate their multi-codec licensing strategies before the December 31, 2025 deadline. Companies implementing both HEVC and next-generation VVC technologies can realize significant cost savings and operational efficiencies through the MCBA structure. Article content The alignment of HEVC rates with VVC rates also creates opportunities for companies to adopt a unified approach to video codec licensing across their product portfolios, simplifying compliance obligations while accessing the industry's most comprehensive patent coverage, and providing maximum flexibility for future technology adoption. Article content For licensing inquiries and detailed rate information, interested parties should contact Access Advance at licensing@ About Access Advance: Article content Access Advance LLC is an independent licensing administrator company formed to lead the development, administration, and management of patent pools for licensing essential patents of the most important video codec technologies. Access Advance provides a transparent and efficient licensing mechanism for both patent owners and patent implementers. Article content Access Advance manages and administers the HEVC Advance Patent Pool for licensing over 27,000 patents essential to H.265/HEVC technology and the VVC Advance Patent Pool for licensing essential patents to VVC/H.266 technology. The company's Multi-Codec Bridging Agreement provides eligible licensees with a single discounted royalty rate structure for licensees participating in both the HEVC Advance and VVC Advance pools. In addition, Access Advance offers the VDP Pool, a comprehensive licensing solution for video streaming services covering HEVC, VVC, VP9, and AV1 codecs. For more information, please visit: Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Meredith Hollander Article content Article content Article content Access Advance LLC Article content Article content Email: Article content press@ Article content Article content Website: Article content Article content Article content
CTV News
19 minutes ago
- CTV News
Stellantis says financial loss caused by Trump tariffs as Brampton plant sits empty
The maker of Jeep, Ram, and Fiat announced a financial loss caused by Trump's tariffs has forced the company to slash production and shipments.
Globe and Mail
an hour ago
- Globe and Mail
BBB Foods: A Rising Star in the Grocery Sector
Explore the exciting world of BBB Foods (NYSE: TBBB) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jun. 11, 2025. The video was published on Jul. 21, 2025. Should you invest $1,000 in Bbb Foods right now? Before you buy stock in Bbb Foods, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bbb Foods wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
